|
Re: Provenge: implications for measuring effectiveness
Mostly pointing out how the usual tumor shrinkage/RECIST criteria gauging of effectiveness didn't predict the survival benefit. I'm wondering whether some therapies, maybe immunotherapies in particular, are abandoned prematurely due to shortsighted criteria. It also might tie into the cancer stem cell theory/issue in that they are considered a less visible but maybe important minority of the cells.
|